WIRB-Copernicus Group snaps up Velos eResearch for undisclosed price

Close-up of handshake between person in suit and person in business shirt.
Clinical research helper WIRB-Copernicus Group acquired Velos eResearch, a clinical trial management solutions provider, for an undisclosed price. (Getty Images)

WIRB-Copernicus Group has boosted its clinical trial management solutions business as it adds CTMS specialist Velos eResearch to its growing family.

The company will tap into Velos' internet platform solution, where it is able to streamline the management of institutional research by linking study status, patient enrollment, calendars, budgets, billing and electronic data capture by centralizing the management of research activities, the company said.

Under terms of the deal, Velos will continue to operate independently and will remain headquartered in Fremont, California.

CONFERENCE

AI Innovations for Life Science and Healthcare Summit East

Join the expert speaking faculty of over 30 life science, healthcare, and tech professionals on June 13–14, 2019, in Philadelphia, as we elevate clinical trial operations, healthcare outcomes, and supply chain implementation through AI. Use Discount Code 796819FIERCE to save 15% off the standard registration rate.

WCG partners with 93% of the institutions—and 90% of the academic medical centers—that conduct research in the U.S., the company said.

“WCG is privileged to serve more than 2,800 institutions, and we are thrilled to empower them with technology solutions that will increase the efficiency of their research programs,” Donald A Deieso, WCG’s chair and CEO, said in a statement.

Last summer, WCG acquired KMR Group and Metrics Consortium in a deal that strengthened the company’s market insights and intelligence division.

Suggested Articles

WIRB-Copernicus Group has added two new executives to its roster as it expands its Global Research Network of investigative sites.

Incoming FDA Commissioner Ned Sharpless used his first official talk to ensure we all know he’s not looking to tear up Scott Gottlieb’s legacy.

Charles River Labs and the CHDI Foundation have signed a five-year extension for their Huntington’s disease work.